LeonaBio Crescita futura

Criteri Future verificati 0/6

Si prevede che LeonaBio aumenterà gli utili e i ricavi rispettivamente del 3.9% e 75.7% all'anno, mentre si prevede che l'EPS crescerà del 50.6% all'anno.

Informazioni chiave

3.9%

Tasso di crescita degli utili

50.59%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	14.5%
Tasso di crescita dei ricavi	75.7%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	08 May 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

Articolo di analisi • Feb 16

Athira Alzheimer's drug trial gets monitoring panel nod to continue after efficacy analysis

Athira Pharma (NASDAQ:ATHA) said an independent data monitoring committee recommended to continue a phase 2/3 trial of fosgonimeton (ATH-1017) to treat patients with mild-to-moderate Alzheimer's disease (AD). The committee made the recommended after an interim efficacy and futility analysis of the study, dubbed LIFT-AD, the company added. In addition, the panel decided that, with the additional enrollment of fewer than 150 patients for a total enrollment of less than 300 people without background therapy (acetylcholinesterase inhibitors), the trial will be well powered for the main goal given the preliminary effect size seen, according to the company. The main goal of the trial is Global Statistical Test, a tool for measuring cognition and function. Athira noted that data from a phase 2 study called ACT-AD had showed a favorable safety profile and suggested positive effects on measures of cognition, function and neurodegeneration in patients taking fosgonimeton without background therapy. ATHA +2.49% to $3.29 premarket Oct. 17

Seeking Alpha • Aug 15

Athira Pharma GAAP EPS of -$0.65

Athira Pharma press release (NASDAQ:ATHA): Q2 GAAP EPS of -$0.65. Cash, cash equivalents and investments were $282.2 million as of June 30, 2022, compared with $319.7 million as of December 31, 2021.

Articolo di analisi • Aug 09

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Seeking Alpha • Jun 22

Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug

Athira Pharma has just read out first Phase 2 results in one of two Alzheimer’s trials. Its drug candidate ATH-1017 targets the HGF/MET pathway, a unique approach which has led to promising Phase 1 data. The readout shows efficacy in a subgroup, underlining validity of the proposed pathway and drug candidate ATH-1017, and I expected this would happen. The company's shares are falling severely on the primary endpoint miss. Simply stated, if the primary endpoint would have been cognition in the monotherapy group, then the results would have been seen as successful, which is why I believe there is potential to be a new Alzheimer's drug in the making here.

Articolo di analisi • May 08

Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Articolo di analisi • Jan 11

We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Seeking Alpha • Jun 29

Athira Pharma: What, Exactly, Did The CEO Do?

CEO Leen Kawas is on leave because she is pending review for allegations of scientific misconduct. The science in question relates to Athira's core work in Alzheimer's. How strongly they are related will determine Athira's future.

Articolo di analisi • May 24

We Think Athira Pharma (NASDAQ:ATHA) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Articolo di analisi • Feb 08

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Articolo di analisi • Dec 18

Here's What Athira Pharma, Inc.'s (NASDAQ:ATHA) Shareholder Ownership Structure Looks Like

The big shareholder groups in Athira Pharma, Inc. ( NASDAQ:ATHA ) have power over the company. Institutions often own...

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:LONA - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Utili	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2028	N/A	-141	-135	N/A	2
12/31/2027	N/A	-119	-112	N/A	2
12/31/2026	N/A	-115	-88	N/A	3
3/31/2026	N/A	-129	-52	-52	N/A
12/31/2025	N/A	-106	-46	-46	N/A
9/30/2025	N/A	-38	-52	-52	N/A
6/30/2025	N/A	-60	-71	-71	N/A
3/31/2025	N/A	-80	-86	-86	N/A
12/31/2024	N/A	-97	-97	-97	N/A
9/30/2024	N/A	-109	-97	-97	N/A
6/30/2024	N/A	-113	-98	-98	N/A
3/31/2024	N/A	-116	-100	-100	N/A
12/31/2023	N/A	-118	-101	-101	N/A
9/30/2023	N/A	-121	-90	-90	N/A
6/30/2023	N/A	-108	-88	-88	N/A
3/31/2023	N/A	-102	-83	-82	N/A
12/31/2022	N/A	-96	-74	-72	N/A
9/30/2022	N/A	-82	-77	-75	N/A
6/30/2022	N/A	-77	-66	-64	N/A
3/31/2022	N/A	-67	-54	-52	N/A
12/31/2021	N/A	-55	-45	-43	N/A
9/30/2021	N/A	-46	-38	-36	N/A
6/30/2021	N/A	-39	-37	-35	N/A
3/31/2021	N/A	-27	-33	-30	N/A
12/31/2020	N/A	-20	-26	-24	N/A
9/30/2020	N/A	-13	-15	-14	N/A
6/30/2020	N/A	-6	-6	-6	N/A
3/31/2020	N/A	-6	-4	-4	N/A
12/31/2019	N/A	-5	N/A	-4	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che LONA rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che LONA rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che LONA rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che LONA non avrà alcun fatturato il prossimo anno.

Ricavi ad alta crescita: Si prevede che LONA non avrà alcun fatturato il prossimo anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di LONA è previsto essere elevato tra 3 anni

Scoprire le aziende in crescita

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2026/05/11 11:42
Prezzo dell'azione a fine giornata	2026/05/08 00:00
Utili	2026/03/31
Utili annuali	2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

LeonaBio, Inc. è coperta da 7 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Esther Lannie Hong	Berenberg
Eric Schmidt	Cantor Fitzgerald & Co.
Jason Butler	Citizens JMP Securities, LLC

LeonaBio Crescita futura

Criteri Future verificati 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target decreased by 46% to US$4.00

Price target increased by 23% to US$9.25

Price target decreased by 33% to US$7.83

Price target increased to US$11.75

Price target increased to US$11.75

Price target decreased to US$15.40

Recent updates

LeonaBio, Inc. announced that it has received $89.724073 million in funding

Leonabio, Inc. Announces the Appointment of Mark F. Kubik as Chief Business Officer

Athira Pharma, Inc. Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate

New major risk - Share price stability

Athira Pharma, Inc. announced that it expects to receive $89.724073 million in funding

Insufficient new directors

New minor risk - Share price stability

Athira Pharma, Inc., Annual General Meeting, May 29, 2025

New major risk - Market cap size

High number of new directors

Athira Pharma Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Global Select Market

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases

Price target decreased by 46% to US$4.00

Athira Pharma, Inc. Announces Topline Results from Phase 2/3 Lift-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease

Athira Pharma Announces Last Patient Completed Lift-Ad Clinical Trial of Fosgonimeton in Mild-To-Moderate Alzheimer’s Disease

New major risk - Financial position

Independent Chairwoman of the Board recently bought US$100k worth of stock

Athira Pharma, Inc. Announces Proposed Settlement of Stockholder Derivative Action

Athira Pharma, Inc. Appoints Javier San Martin, M.D., as Chief Medical Officer

Athira Pharma, Inc. Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease

Athira Pharma, Inc., Annual General Meeting, May 23, 2024

New minor risk - Market cap size

Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?

Athira Pharma, Inc. Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Athira Pharma, Inc. Announces Hans Moebius Retires as Chief Medical Officer

Price target increased by 23% to US$9.25

Athira Pharma, Inc. Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid-B-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's Disease

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

New minor risk - Market cap size

Athira Pharma, Inc. Appoints Andrew Gengos as Chief Financial Officer

Athira Pharma, Inc. Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer’s Disease

CFO & Chief Business Officer recently bought US$192k worth of stock

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Athira Pharma, Inc. Announces the Appointment of Andrew Gengos as Chief Business Officer

Athira Pharma, Inc. Announces CFO Changes

Independent Director recently bought US$60k worth of stock

Price target decreased by 33% to US$7.83

Athira Pharma Announces Promotion of Kevin Church to Chief Scientific Officer

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?

Chief Financial Officer recently bought US$142k worth of stock

Athira Pharma, Inc. Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics

Independent Chairwoman of the Board recently bought US$99k worth of stock

Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND

Price target increased to US$11.75

High number of new and inexperienced directors

Athira Pharma Advances Phase 2/3 Lift-Ad Clinical Study of Fosgonimeton in Mild-To Moderate Alzheimer's Patients Following Independent, Unblinded Interim Analysis

Price target increased to US$11.75

Athira Alzheimer's drug trial gets monitoring panel nod to continue after efficacy analysis

Athira Pharma, Inc. Provides Update on Plans for Ongoing LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients

Athira Pharma GAAP EPS of -$0.65

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients at the Alzheimer's Association International Conference 2022

Price target decreased to US$15.40

Athira Pharma, Inc. Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease

Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug

Athira Pharma, Inc. Announces New Board Appointments

Richard A Kayne Issues Letter to Shareholders of Athira Pharma Inc

Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer’s Disease

Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth

Richard A Kayne Communicates with Athira Pharma Inc

High number of new and inexperienced directors

Richard A. Kayne Files an Investor Presentation to Shareholders of Athira Pharma

Richard A. Kayne Provides Information to Shareholders of Athira Pharma Inc

Athira Pharma, Inc., Annual General Meeting, May 19, 2022

Athira Pharma, Inc. Doses First Subject in Phase 1 Clinical Trial of HGF/MET Positive Modulator, ATH-1020, an Orally Available Small Molecule for Neuropsychiatric Conditions

Independent Chairman of the Board recently bought US$105k worth of stock

Richard A. Kayne Sends Provides Information to Shareholders of Athira Pharma Inc

Athira Pharma, Inc. Presents Preclinical Data of Fosgonimeton (ATH-1017) and ATH-1020 at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting

Athira Pharma, Inc. Announces Publication of Phase 1 Results for Fosgonimeton (ATH-1017) in The Journal of Alzheimer's Disease